참고문헌

1. CADTH. CADTH database search filters [Internet]. 2016 [cited 2017 02.04]; Available from: https://www.cadth.ca/resources/finding-evidence/strings-attached-cadths-database-searc h-filters#guide.
2. Nicolle, L.E., et al., Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis, 2005. 40(5): p. 643-54.
3. Grabe, M., et al., Guidelines on urological infections. 2015 [cited 2017 Jul 07]; Available from: https://uroweb.org/wp-content/uploads/19-Urological-infections_LR2.pdf.
4. Dull, R.B., et al., Antimicrobial treatment of asymptomatic bacteriuria in noncatheterized adults: a systematic review. Pharmacotherapy, 2014. 34(9): p. 941-60.
5. Nicolle, L.E., Asymptomatic bacteriuria. Current Opinion in Infectious Diseases, 2014. 27(1): p. 90-6.
6. Nicolle, L.E., The Paradigm Shift to Non-Treatment of Asymptomatic Bacteriuria. Pathogens, 2016. 5(2).
7. Bengtsson, C., et al., Bacteriuria in a population sample of women: 24-year follow-up study. Results from the prospective population-based study of women in Gothenburg, Sweden. Scand J Urol Nephrol, 1998. 32(4): p. 284-9.
8. Evans, D.A., et al., Bacteriuria in a population-based cohort of women. J Infect Dis, 1978. 138(6): p. 768-73.
9. Jeon, M.H., et al., Korean Nosocomial Infections Surveillance System, Intensive Care Unit Module Report: Data Summary from July 2010 through June 2011. Korean J Nosocomial Infect Control, 2012. 17(1): p. 28-39.
10. Shin, J.C., et al., Difference of Organism and Their Antibiotics Sensitivity from Urine Culture in Symptomatic Urinary Tract Infection of Spinal Cord Injury Patients. J Korean Acad Rehabil Med, 2008. 32(1): p. 38-44.
11. Smaill, F.M. and J.C. Vazquez, Antibiotics for asymptomatic bacteriuria in pregnancy. Cochrane Database of Systematic Reviews, 2015(8): p. CD000490.
12. Kazemier, B.M., et al., Maternal and neonatal consequences of treated and untreated asymptomatic bacteriuria in pregnancy: a prospective cohort study with an embedded randomised controlled trial. Lancet Infect Dis, 2015. 15(11): p. 1324-33.
13. Angelescu, K., et al., Benefits and harms of screening for and treatment of asymptomatic bacteriuria in pregnancy: a systematic review. BMC Pregnancy Childbirth, 2016. 16(1): p. 336.
14. Cai, T., et al., The role of asymptomatic bacteriuria in young women with recurrent urinary tract infections: to treat or not to treat? Clinical Infectious Diseases, 2012. 55(6): p. 771-7.
15. Cai, T., et al., Asymptomatic bacteriuria treatment is associated with a higher prevalence of antibiotic resistant strains in women with urinary tract infections. Clinical Infectious Diseases, 2015. 61(11): p. 1655-61.
16. Boscia, J.A., et al., Therapy vs no therapy for bacteriuria in elderly ambulatory nonhospitalized women. JAMA, 1987. 257(8): p. 1067-71.
17. Abrutyn, E., et al., Does asymptomatic bacteriuria predict mortality and does antimicrobial treatment reduce mortality in elderly ambulatory women? Ann Intern Med, 1994. 120(10): p. 827-33
18. Nicolle, L.E., W.J. Mayhew, and L. Bryan, Prospective randomized comparison of therapy and no therapy for asymptomatic bacteriuria in institutionalized elderly women. Am J Med, 1987. 83(1): p. 27-33.
19. Ouslander, J.G., et al., Does eradicating bacteriuria affect the severity of chronic urinary incontinence in nursing home residents? Ann Intern Med, 1995. 122(10): p. 749-54.
20. Harding, G.K., et al., Antimicrobial treatment in diabetic women with asymptomatic bacteriuria. N Engl J Med, 2002. 347(20): p. 1576-83.
21. Dalal, S., et al., Long-term Escherichia coli asymptomatic bacteriuria among women with diabetes mellitus. Clin Infect Dis, 2009. 49(4): p. 491-7.
22. Mohler, J.L., D.L. Cowen, and R.C. Flanigan, Suppression and treatment of urinary tract infection in patients with an intermittently catheterized neurogenic bladder. J Urol, 1987. 138(2): p. 336-40.
23. Maynard, F.M. and A.C. Diokno, Urinary infection and complications during clean intermittent catheterization following spinal cord injury. J Urol, 1984. 132(5): p. 943-6.
24. Harding, G.K., et al., How long should catheter-acquired urinary tract infection in women be treated? A randomized controlled study. Ann Intern Med, 1991. 114(9): p. 713-9.
25. Warren, J.W., et al., Cephalexin for susceptible bacteriuria in afebrile, long-term catheterized patients. JAMA, 1982. 248(4): p. 454-8.
26. Leone, M., et al., A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients. Intensive Care Med, 2007. 33(4): p. 726-9.
27. Hooton, T.M., et al., Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clin Infect Dis, 2010. 50(5): p. 625-63.
28. Grabe, M., et al., Controlled trial of a short and a prolonged course with ciprofloxacin in patients undergoing transurethral prostatic surgery. Eur J Clin Microbiol, 1987. 6(1): p. 11-7
29. Olsen, J.H., et al., Cefotaxime for prevention of infectious complications in bacteriuric men undergoing transurethral prostatic resection. A controlled comparison with methenamine. Scand J Urol Nephrol, 1983. 17(3): p. 299-301.
30. Grabe, M., A. Forsgren, and S. Hellsten, The effect of a short antibiotic course in transurethral prostatic resection. Scand J Urol Nephrol, 1984. 18(1): p. 37-42.
31. Allan, W.R. and A. Kumar, Prophylactic mezlocillin for transurethral prostatectomy. Br J Urol, 1985. 57(1): p. 46-9.
32. Rao, P.N., et al., Prediction of septicemia following endourological manipulation for stones in the upper urinary tract. J Urol, 1991. 146(4): p. 955-60
33. Cafferkey, M.T., et al., Antibiotics for the prevention of septicaemia in urology. J Antimicrob Chemother, 1982. 9(6): p. 471-7
34. Nicolle, L.E., Uncomplicated urinary tract infection in adults including uncomplicated pyelonephritis. Urol Clin North Am, 2008. 35(1): p. 1-12, v.
35. 의약품 소비량 심층분석, 건. 보건복지부, Editor. 2015.
36. Mazzulli, T., Resistance trends in urinary tract pathogens and impact on management. J Urol, 2002. 168(4 Pt 2): p. 1720-2.
37. Lee, S.J., et al., Antimicrobial resistance in community-acquired urinary tract infections: results from the Korean Antimicrobial Resistance Monitoring System. J Infect Chemother, 2011. 17(3): p. 440-6.
38. Kim, B., et al., Is it Acceptable to Select Antibiotics for the Treatment of Community-acquired Acute Cystitis Based on the Antibiotics Susceptibility Results for Uropathogens from Community-acquired Acute Pyelonephritis in Korea? Infect Chemother, 2012. 44(4): p. 269-274.
39. Lee, S.J., et al., Antimicrobial susceptibility of uropathogens causing acute uncomplicated cystitis in female outpatients in South Korea: a multicentre study in 2002. Int J Antimicrob Agents, 2004. 24 Suppl 1: p. S61-4.
40. Kim, M.E., U.S. Ha, and Y.H. Cho, Prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in female outpatients in South Korea: a multicentre study in 2006. Int J Antimicrob Agents, 2008. 31 Suppl 1: p. S15-8.
41. Kim, H.Y., et al., Microbiological Characteristics of Unresolved Acute Uncomplicated Cystitis. Microb Drug Resist, 2016. 22(5): p. 387-91.
42. Kim, W.B., et al., Recent Antimicrobial Susceptibilities for Uropathogenic Escherichia coli in Patients with Community Acquired Urinary Tract Infections: A Multicenter Study. Urogenit Tract Infect, 2017. 12(1): p. 28-34.
43. Kim, K.Y., C.S. Kim, and D.H. Lim, The Ciprofloxacin Resistance Pattern of Escherichia coli Isolated from Female Patients with Community-acquired Urinary Tract Infection in the Jeonnam and Gwangju Region for the Recent 2-years. Korean J Urol, 2008. 49(6): p. 540-548.
44. Clinical Guideline for the Diagnosis and Treatment of Urinary Tract Infections: Asymptomatic Bacteriuria, Uncomplicated & Complicated Urinary Tract Infections, Bacterial Prostatitis. Infect Chemother, 2011. 43(1): p. 1-25.
45. Bent, S., et al., Does this woman have an acute uncomplicated urinary tract infection? Jama, 2002. 287(20): p. 2701-10.
46. Rowe, T.A. and M. Juthani-Mehta, Diagnosis and management of urinary tract infection in older adults. Infect Dis Clin North Am, 2014. 28(1): p. 75-89.
47. Grabe, M., et al., Guidelines on Urological Infections. 2015; 86. Available from: http://uroweb.org/wp-content/uploads/EAU-Guidelines-Urological-Infections-v2.pdf.
48. Rubin, R.H., et al., Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis, 1992. 15 Suppl 1: p. S216-27.
49. Zalmanovici Trestioreanu, A., et al., Antimicrobial agents for treating uncomplicated urinary tract infection in women. Cochrane Database Syst Rev, 2010(10): p. Cd007182.
50. Rafalsky, V., I. Andreeva, and E. Rjabkova, Quinolones for uncomplicated acute cystitis in women. Cochrane Database Syst Rev, 2006(3): p. Cd003597.
51. Information for Healthcare Professionals: Fluoroquinolone Antimicrobial Drugs [ciprofloxacin (marketed as Cipro and generic ciprofloxacin), ciprofloxacin extended-release (marketed as Cipro XR and Proquin XR), gemifloxacin (marketed as Factive), levofloxacin (marketed as Levaquin), moxifloxacin (marketed as Avelox), norfloxacin (marketed as Noroxin), and ofloxacin (marketed as Floxin)]. Available from: https://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm126085.htm.
52. Falagas, M.E., et al., Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials. J Antimicrob Chemother, 2010. 65(9): p. 1862-77.
53. Schito, G.C., et al., The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int J Antimicrob Agents, 2009. 34(5): p. 407-13.
54. Zhanel, G.G., A.J. Walkty, and J.A. Karlowsky, Fosfomycin: A First-Line Oral Therapy for Acute Uncomplicated Cystitis. Can J Infect Dis Med Microbiol, 2016. 2016: p. 2082693.
55. Seo, M.R., et al., Susceptibility of Escherichia coli from community-acquired urinary tract infection to fosfomycin, nitrofurantoin, and temocillin in Korea. J Korean Med Sci, 2014. 29(8): p. 1178-81.
56. Hooton, T. M., Roberts, P. L., and Stapleton, A. E., Cefpodoxime vs ciprofloxacin for short-course treatment of acute uncomplicated cystitis: a randomized trial. Jama, 2012. 307(6): p. 583-589.
57. Kavatha, D., et al., Cefpodoxime-proxetil versus trimethoprim-sulfamethoxazole for short-term therapy of uncomplicated acute cystitis in women. Antimicrobial agents and chemotherapy, 2003. 47(3): p. 897-900.
58. Raz, R., Rottensterich, E., Leshem, Y., and Tabenkin, H. Double-blind study comparing 3-day regimens of cefixime and ofloxacin in treatment of uncomplicated urinary tract infections in women. Antimicrobial agents and chemotherapy, 1994. 38(5): p. 1176-1177.
59. Galkin, V. V., Malev, I. V., Kozlov, S. N., and Rafal'skii, V. V. Efficacy and safety of cefixim and ciprofloxacin in acute cystitis (a multicenter randomized trial). Urologiia (Moscow, Russia: 1999), 2011. (1): p. 13-16.
60. Lee, S.-J., et al., Efficacy of Cefcapene Pivoxil for Empirical Therapy of Acute Uncomplicated Cystitis. Infect Chemother, 2008. 40(3): p. 162-166.
61. Sohn, D. W., Ha, U., Seo, H. J., Lee, J. Y., Kim, S. W., and Cho, Y. H. In-vitro susceptibility study of oral antibiotics to Escherichia coli, isolated from acute uncomplicated cystitis in female outpatients. Infection and Chemotherapy, 2006. 38(3): p. 140-145.
62. Roh, K. H., et al., In vitro activities of cefatrizine-clavulanic acid against gram-negative bacilli isolated from community-acquired urinary track infection. The Korean Journal of Laboratory Medicine, 2005. 25(6): p. 411-415.
63. Lee, S.Y., et al., Susceptibility tests of oral antibiotics including cefixime against Escherichia coli, isolated from pediatric patients withcommunity acquired urinary tract infections. Korean J Pediatr, 2006. 49(7): p. 777-783.
64. Warren, J.W., et al., Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis, 1999. 29(4): p. 745-58.
65. Kim, J.H., et al., Prevalence of antibiotic susceptibility and resistance of Escherichia coli in acute uncomplicated cystitis in Korea: Systematic review and meta-analysis. Medicine (Baltimore), 2016. 95(36): p. e4663.
66. Pinart, M., et al., Optimal dosage and duration of pivmecillinam treatment for uncomplicated lower urinary tract infections: a systematic review and meta-analysis. Int J Infect Dis, 2017. 58: p. 96-109.
67. Milo, G., et al., Duration of antibacterial treatment for uncomplicated urinary tract infection in women. Cochrane Database Syst Rev, 2005(2): p. Cd004682.
68. Lutters, M. and N.B. Vogt-Ferrier, Antibiotic duration for treating uncomplicated, symptomatic lower urinary tract infections in elderly women. Cochrane Database Syst Rev, 2008(3): p. Cd001535.
69. Sadahira, T., et al., Efficacy and safety of 3 day versus 7 day cefditoren pivoxil regimens for acute uncomplicated cystitis: multicentre, randomized, open-label trial. J Antimicrob Chemother, 2017. 72(2): p. 529-534.
70. Grigoryan, L., et al., Less workup, longer treatment, but no clinical benefit observed in women with diabetes and acute cystitis. Diabetes Res Clin Pract, 2017. 129: p. 197-202.
71. Katchman, E.A., et al., Three-day vs longer duration of antibiotic treatment for cystitis in women: systematic review and meta-analysis. Am J Med, 2005. 118(11): p. 1196-207.
72. Lifshitz, E. and L. Kramer, Outpatient urine culture: does collection technique matter? Arch Intern Med, 2000. 160(16): p. 2537-40.
73. Bradbury, S.M., Collection of urine specimens in general practice: to clean or not to clean? J R Coll Gen Pract, 1988. 38(313): p. 363-5.
74. Barry, H.C., M.H. Ebell, and J. Hickner, Evaluation of suspected urinary tract infection in ambulatory women: a cost-utility analysis of office-based strategies. J Fam Pract, 1997. 44(1): p. 49-60.
75. Carlson, K.J. and A.G. Mulley, Management of acute dysuria. A decision-analysis model of alternative strategies. Ann Intern Med, 1985. 102(2): p. 244-9.
76. Foxman, B., Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Dis Mon, 2003. 49(2): p. 53-70.
77. Kunin, C.M., Urinary tract infections in females. Clin Infect Dis, 1994. 18(1): p. 1-10; quiz 11-2.
78. Hooton, T.M., Clinical practice. Uncomplicated urinary tract infection. N Engl J Med, 2012. 366(11): p. 1028-37.
79. Ki, M., et al., The epidemiology of acute pyelonephritis in South Korea, 1997-1999. Am J Epidemiol, 2004. 160(10): p. 985-93.
80. Scholes, D., et al., Risk factors associated with acute pyelonephritis in healthy women. Ann Intern Med, 2005. 142(1): p. 20-7.
81. Czaja, C.A. and T.M. Hooton, Update on acute uncomplicated urinary tract infection in women. Postgrad Med, 2006. 119(1): p. 39-45.
82. Ramakrishnan, K. and D.C. Scheid, Diagnosis and management of acute pyelonephritis in adults. Am Fam Physician, 2005. 71(5): p. 933-42.
83. Efstathiou, S.P., et al., Acute pyelonephritis in adults: prediction of mortality and failure of treatment. Arch Intern Med, 2003. 163(10): p. 1206-12.
84. Farrell, D.J., et al., A UK multicentre study of the antimicrobial susceptibility of bacterial pathogens causing urinary tract infection. J Infect, 2003. 46(2): p. 94-100.
85. Wie, S. H., et al., Clinical features and antimicrobial resistance among clinical isolates of women with community-acquired acute pyelonephritis in 2001-2006. Infection and Chemotherapy, 2007. 39(1): p. 9-16.
86. Hwang, B. Y., et al., Antimicrobial susceptibility of causative microorganisms in adults with acute pyelonephritis at one university-affiliated hospital in southwestern Seoul. Infection and Chemotherapy, 2003. 35(5): p. 277-282.
87. Wie SH, et al., Antibiotic sensitivity of the causative organisms and use of antibitiotics in women with community-acquired acute pyelonephritis. Korean Journal of Infectious Diseases, 2002. 34: p. 353-359.
88. The Korean Society of Infectious Diseases, The Korean Society for Chemotherapy, Korean Association of Urogenital Tract Infection, The Korean Society of Clinical Microbiology, Clinical guideline for the diagnosis and treatment of urinary tract infections: asymptomatic bacteriuria, uncomplicated & complicated urinary tract infections, bacterial prostatitis. Infection & Chemotherapy, 2011. 43: p. 1-25.
89. Kim, B., et al., Clinical characteristics of community-acquired acute pyelonephritis caused by ESBL-producing pathogens in South Korea. Infection, 2013. 41(3): p. 603-12.
90. Sanchez, G.V., et al., In vitro antimicrobial resistance of urinary Escherichia coli isolates among U.S. outpatients from 2000 to 2010. Antimicrob Agents Chemother, 2012. 56(4): p. 2181-3.
91. Wie, S.H., et al., Clinical characteristics predicting early clinical failure after 72 h of antibiotic treatment in women with community-onset acute pyelonephritis: a prospective multicentre study. Clin Microbiol Infect, 2014. 20(10): p. O721-9.
92. SH, W., Urinary tract infection, in Infectious Diseases, The Korean Society of Infectious Diseases, Editor. 2014: Seoul. p. 225-237.
93. National Guideline, C., ACR Appropriateness Criteria® acute pyelonephritis. 2012.
94. Gupta, K., et al., International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis, 2011. 52(5): p. e103-20.
95. Neumann, I. and P. Moore, Pyelonephritis (acute) in non-pregnant women. BMJ Clin Evid, 2014. 2014.
96. Czaja, C.A., et al., Population-based epidemiologic analysis of acute pyelonephritis. Clin Infect Dis, 2007. 45(3): p. 273-80.
97. van der Starre, W.E., J.T. van Dissel, and C. van Nieuwkoop, Treatment duration of febrile urinary tract infections. Curr Infect Dis Rep, 2011. 13(6): p. 571-8.
98. Jeon, J.H., et al., Empirical use of ciprofloxacin for acute uncomplicated pyelonephritis caused by Escherichia coli in communities where the prevalence of fluoroquinolone resistance is high. Antimicrob Agents Chemother, 2012. 56(6): p. 3043-6.
99. Talan, D.A., et al., Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial. JAMA, 2000. 283(12): p. 1583-90.
100. Stamm, W.E., M. McKevitt, and G.W. Counts, Acute renal infection in women: treatment with trimethoprim-sulfamethoxazole or ampicillin for two or six weeks. A randomized trial. Ann Intern Med, 1987. 106(3): p. 341-5.
101. Klausner, H.A., et al., A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis. Curr Med Res Opin, 2007. 23(11): p. 2637-45.
102. Talan, D.A., et al., Once daily, extended release ciprofloxacin for complicated urinary tract infections and acute uncomplicated pyelonephritis. J Urol, 2004. 171(2 Pt 1): p. 734-9.
103. Cronberg, S., et al., Fewer bacterial relapses after oral treatment with norfloxacin than with ceftibuten in acute pyelonephritis initially treated with intravenous cefuroxime. Scand J Infect Dis, 2001. 33(5): p. 339-43.
104. Wagenlehner, F.M., W. Weidner, and K.G. Naber, An update on uncomplicated urinary tract infections in women. Curr Opin Urol, 2009. 19(4): p. 368-74.
105. Sandberg, T., et al., Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial. Lancet, 2012. 380(9840): p. 484-90.
106. van Nieuwkoop, C., et al., Treatment duration of febrile urinary tract infection: a pragmatic randomized, double-blind, placebo-controlled non-inferiority trial in men and women. BMC Med, 2017. 15(1): p. 70.
107. Chang, U.I., H.W. Kim, and S.H. Wie, Use of cefuroxime for women with community-onset acute pyelonephritis caused by cefuroxime-susceptible or -resistant Escherichia coli. Korean J Intern Med, 2016. 31(1): p. 145-55.
108. Chang, U.I., H.W. Kim, and S.H. Wie, Comparison of Second- and Third-Generation Cephalosporin as Initial Therapy for Women with Community-Onset Uncomplicated Acute Pyelonephritis. Yonsei Med J, 2015. 56(5): p. 1266-73.
109. Bader, M.S., M. Loeb, and A.A. Brooks, An update on the management of urinary tract infections in the era of antimicrobial resistance. Postgrad Med, 2017. 129(2): p. 242-258.
110. Ipekci, T., et al., Clinical and bacteriological efficacy of amikacin in the treatment of lower urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella pneumoniae. J Infect Chemother, 2014. 20(12): p. 762-7.
111. Pietrucha-Dilanchian, P. and T.M. Hooton, Diagnosis, Treatment, and Prevention of Urinary Tract Infection. Microbiol Spectr, 2016. 4(6).
112. Veve, M.P., et al., Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum beta-lactamase urinary tract infections. Int J Antimicrob Agents, 2016. 48(1): p. 56-60.
113. Tamma, P.D., et al., The use of cefepime for treating AmpC beta-lactamase-producing Enterobacteriaceae. Clin Infect Dis, 2013. 57(6): p. 781-8.
114. Wagenlehner, F.M., et al., Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program. Clin Infect Dis, 2016. 63(6): p. 754-762.
115. Wagenlehner, F.M., et al., Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet, 2015. 385(9981): p. 1949-56.
116. Rodriguez-Bano, J., et al., beta-Lactam/beta-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis, 2012. 54(2): p. 167-74.
117. Kang, C.I., et al., Piperacillin-tazobactam as an initial empirical therapy of bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. J Infect, 2012. 64(5): p. 533-4.
118. Cho, S.Y., et al., Amikacin therapy for urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Korean J Intern Med, 2016. 31(1): p. 156-61.
119. Klahr, S., Obstructive nephropathy. Intern Med, 2000. 39(5): p. 355-61.
120. Reyner, K., A.C. Heffner, and C.H. Karvetski, Urinary obstruction is an important complicating factor in patients with septic shock due to urinary infection. American Journal of Emergency Medicine, 2016. 34(4): p. 694-6.
121. Heyns, C.F., Urinary tract infection associated with conditions causing urinary tract obstruction and stasis, excluding urolithiasis and neuropathic bladder. World Journal of Urology, 2012. 30(1): p. 77-83.
122. Kim, S. and C. Wang, A clinical observation on 131 cases of hydronephrosis. Korean Journal of Urology, 1978. 19: p. 89-97.
123. Romero Culleres, G., et al., [Characteristics of urinary tract infections in different patient subpopulations and depending on the bladder emptying system]. Actas Urol Esp, 2010. 34(3): p. 251-7.
124. Marien, T. and N.L. Miller, Treatment of the Infected Stone. Urologic Clinics of North America, 2015. 42(4): p. 459-72.
125. Brown, P.D., Management of urinary tract infections associated with nephrolithiasis. Current Infectious Disease Reports, 2010. 12(6): p. 450-4.
126. Roy, C., et al., Emphysematous pyelitis: findings in five patients. Radiology, 2001. 218(3): p. 647-50.
127. Olvera-Posada, D., et al., Emphysematous pyelonephritis: multicenter clinical and therapeutic experience in Mexico. Urology, 2014. 83(6): p. 1280-4.
128. Somani, B.K., et al., Is percutaneous drainage the new gold standard in the management of emphysematous pyelonephritis? Evidence from a systematic review. J Urol, 2008. 179(5): p. 1844-9.
129. Hamasuna, R., et al., Obstructive pyelonephritis as a result of urolithiasis in Japan: diagnosis, treatment and prognosis. International Journal of Urology, 2015. 22(3): p. 294-300.
130. Wagenlehner, F.M., et al., Diagnosis and management for urosepsis. International Journal of Urology, 2013. 20(10): p. 963-70.
131. Cha, M.K., et al., In vitro activities of 21 antimicrobial agents alone and in combination with aminoglycosides or fluoroquinolones against extended-spectrum-beta-lactamase-producing Escherichia coli isolates causing bacteremia. Antimicrob Agents Chemother, 2015. 59(9): p. 5834-7.
132. Ramsey, S., et al., Evidence-based drainage of infected hydronephrosis secondary to ureteric calculi. Journal of Endourology, 2010. 24(2): p. 185-9.
133. Aboumarzouk, O.M., et al., Emphysematous pyelonephritis: Time for a management plan with an evidence-based approach. Arab Journal of Urology Print, 2014. 12(2): p. 106-15.
134. Huang, J.J. and C.C. Tseng, Emphysematous pyelonephritis: clinicoradiological classification, management, prognosis, and pathogenesis. Arch Intern Med, 2000. 160(6): p. 797-805.
135. Kolla, P.K., et al., Clinical profile and outcome of conservatively managed emphysematous pyelonephritis. Isrn Urology Print, 2012. 2012: p. 931982.
136. Bjurlin, M.A., et al., Clinical outcomes of nonoperative management in emphysematous urinary tract infections. Urology, 2012. 79(6): p. 1281-5.
137. Nickel, J.C., et al., Category III chronic prostatitis/chronic pelvic pain syndrome: insights from the National Institutes of Health Chronic Prostatitis Collaborative Research Network studies. Curr Urol Rep, 2008. 9(4): p. 320-7.
138. Weidner, W., et al., Chronic prostatitis: a thorough search for etiologically involved microorganisms in 1,461 patients. Infection, 1991. 19 Suppl 3: p. S119-25.
139. Nickel, J.C., et al., Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int, 1999. 84(9): p. 976-81.
140. Nelson, W.G., et al., The role of inflammation in the pathogenesis of prostate cancer. J Urol, 2004. 172(5 Pt 2): p. S6-11; discussion S11-2.
141. Krieger, J.N., L. Nyberg, Jr., and J.C. Nickel, NIH consensus definition and classification of prostatitis. Jama, 1999. 282(3): p. 236-7.
142. Leigh, D.A., Prostatitis--an increasing clinical problem for diagnosis and management. J Antimicrob Chemother, 1993. 32 Suppl A: p. 1-9.
143. Ludwig, M., Diagnosis and therapy of acute prostatitis, epididymitis and orchitis. Andrologia, 2008. 40(2): p. 76-80.
144. Kravchick, S., et al., Acute prostatitis in middle-aged men: a prospective study. BJU Int, 2004. 93(1): p. 93-6.
145. Ha, U.S., et al., Acute bacterial prostatitis in Korea: clinical outcome, including symptoms, management, microbiology and course of disease. Int J Antimicrob Agents, 2008. 31 Suppl 1: p. S96-101.
146. Brede, C.M. and D.A. Shoskes, The etiology and management of acute prostatitis. Nat Rev Urol, 2011. 8(4): p. 207-12.
147. Sharp, V.J., E.B. Takacs, and C.R. Powell, Prostatitis: diagnosis and treatment. Am Fam Physician, 2010. 82(4): p. 397-406.
148. Groen, J., et al., Summary of European Association of Urology (EAU) Guidelines on Neuro-Urology. Eur Urol, 2016. 69(2): p. 324-33.
149. Lipsky, B.A., I. Byren, and C.T. Hoey, Treatment of bacterial prostatitis. Clin Infect Dis, 2010. 50(12): p. 1641-52.
150. Etienne, M., et al., Acute bacterial prostatitis: heterogeneity in diagnostic criteria and management. Retrospective multicentric analysis of 371 patients diagnosed with acute prostatitis. BMC Infect Dis, 2008. 8: p. 12.
151. Charalabopoulos, K., et al., Penetration of antimicrobial agents into the prostate. Chemotherapy, 2003. 49(6): p. 269-79.
152. Millan-Rodriguez, F., et al., Acute bacterial prostatitis: two different sub-categories according to a previous manipulation of the lower urinary tract. World J Urol, 2006. 24(1): p. 45-50.
153. Nickel, J.C., The use of alpha1-adrenoceptor antagonists in lower urinary tract symptoms: beyond benign prostatic hyperplasia. Urology, 2003. 62(3 Suppl 1): p. 34-41.
154. Wagenlehner, F.M., et al., Bacterial prostatitis. World J Urol, 2013. 31(4): p. 711-6
155. Yoon, B.I., et al., Acute bacterial prostatitis: how to prevent and manage chronic infection? J Infect Chemother, 2012. 18(4): p. 444-50.
156. Meares, E.M., Jr., Prostatic abscess. J Urol, 1986. 136(6): p. 1281-2.
157. Meares, E.M., Jr., Acute and chronic prostatitis: diagnosis and treatment. Infect Dis Clin North Am, 1987. 1(4): p. 855-73.